@conference{962d9b2d4e264132b427bf74544e3e3d,
title = "Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.",
author = "Alexander, {Brian Michael} and Ahluwalia, {Manmeet Singh} and Desai, {Arati Suvas} and Jorg Dietrich and Kaley, {Thomas Joseph} and Peereboom, {David M.} and Naoko Takebe and Supko, {Jeffrey G.} and Serena Desideri and Fisher, {Joy D.} and Megan Sims and Xiaobu Ye and Nabors, {Louis B.} and Grossman, {Stuart A.} and Wen, {Patrick Y.}",
note = "2005 Background: The standard of care treatment for newly diagnosed GBM is maximal safe surgical resection followed by two DNA damaging agents, RT and TMZ. Cellular response to DNA damage involves checkpoints that halt the cell cycle to allow DNA repair.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2017",
month = may,
day = "30",
doi = "10.1200/JCO.2017.35.15_SUPPL.2005",
language = "American English",
}